#4

0430

MAR 1 2 2002 A

Dkt. 0575/57474-A/JPW/ADM

EMARIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ronald Breslow et al.

U.S. Serial No. : 10/054,585

Filed: November 12, 2001

For : BETACYCLODEXTRIN DIMERS AND

PHTHALOCYANINES AND USES THEREOF

1185 Avenue of the Americas New York, New York 10036

March 8, 2002

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

<u>Information Disclosure Statement</u> <u>Under 37 C.F.R §1.97(b)(3)</u>

In accordance with their duty of disclosure under 37 C.F.R. § 1.56, applicants would like to direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (Exhibit A) and copies of which are attached hereto as Exhibits 1-17:

- U.S. Patent No. US 6,331,530 B1, issued December 18, 2001, Breslow et al. (Exhibit 1);
- U.S. Patent No. 5,705,662, issued January 6, 1998, McCapra (Exhibit 2);
- 3. U.S. Patent No. 5,552,134, issued September 3, 1996, Morgan and Selman (Exhibit 3);
- 4. U.S. Patent No. 5,438,051, issued August 1, 1995, Morgan and Selman (Exhibit 4);

Ronald Breslow et al. Serial No.: 10/054,585 Filed: November 12, 2001 Page 2

- 5. U.S. Patent No. 5,250,668, issued October 5, 1993, Morgan and Selman (Exhibit 5);
- U.S. Patent No. 5,109,129, issued April 28, 1992,
 Morgan and Selman (Exhibit 6);
- 7. U.S. Patent No. US 4,988,808, issued January 29, 1991, Morgan and Selman (Exhibit 7);
- 8. U.S. Patent No. 5,482,719, issued January 9, 1996, Guillet and Bakhtiyari (Exhibit 8);
- 9. German Patent DE 196 20 154 A1, published March 20, 1997 (Exhibit 9);
- 10. Breslow, R. et al. Sequence selective binding of peptides by artificial receptors in aqueous solution. J. Am. Chem. Soc. 120: 3536-3537, Web publication date March 28, 1998 (Exhibit 10);
- 11. Breslow, R., Halfon, S., and Zhang, B. (1995) Molecular recognition by cyclodextrin dimers. Tetrahedron 51: 377-388 (Exhibit 11);
- Moser, J.G., Heuermann, A., Oehr, P., Scheer, H., Vervoots, A., and Andrees, S. (1994) Carrier systems in PDT: On the way to novel anti-tumor drugs. SIPE Conf. Proc. Vol. 2325 Photodynamic Therapy Of Cancer II, pp 92-99 (Exhibit 12);
- 13. Moser, J.G., Ruebner, A., Vervoots, A., and Wagner, B. (1996) Cyclodextrin dimers used to prevent side effects of photochemotherapy and general tumor chemotherapy. In: Szejtli, J. and Szente, L. (eds.), Proceedings of the Eight

Ronald Breslow et al. Serial No.: 10/054,585 Filed: November 12, 2001 Page 3

International Symposium on Cyclodextrons, Kluwer Academic Publishers, pp 71-76 (Exhibit 13);

- 14. Ruebner, A. et al. (1996) Synthesis Of β-cyclodextrin dimers as carrier systems for photodynamic therapy of cancer. In: Szejtli, J. and Szente, L. (eds.), Proceedings of the Eight International Symposium on Cyclodextrons, Kluwer Academic Publishers, pp 77-80 (Exhibit 14);
- 15. Ruebner, A. et al. (1997) Dimeric cyclodextrin carriers with high binding affinity to porphyrinoid photosensitizers. Journal of Inclusion Phenomena and Molecular Recognition in Chemistry 27: 69-84 (Exhibit 15);
- 16. Ruebner, A. et al. (1999) A cyclodextrin dimer with a photocleavable linker as a possible carrier for the photosensitizer in photodynamic tumor therapy. Proceedings of the National Academy of Sciences 96 (26): 14692-14693 (Exhibit 16); and
- 17. Sauter, M. and Adam, W. (1995) Oxyfunctionalization of benzofurans by singlet oxygen, dioxiranes, and peracids: chemical model studies for the DNA-damaging activity of benzofuran dioxetanes (oxidation) and epoxides (alkylation). Acc. Chem. Res. 28: 289-298 (Exhibit 17).

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Ronald Breslow et al. Serial No.: 10/054,585 Filed: November 12, 2001 Page 4

Applicants are filing this Information Disclosure Statement under 37 C.F.R §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Information Disclosure However, if a fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully Submitted,

hereby certify that correspondence is being deposited this date with the U.S. Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Alan D. Miller Reg. No. 42,889

Date

John P. White Registration No. 28,678 Alan D. Miller Registration No. 42,889 Attorneys for Applicants Cooper & Dunham LLP 1185 Avenue of the Americas New York, New York 10036 (212) 278-0400